Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

Hair loss treatments like Dutasteride, RU58841, and Minoxidil may not work for everyone, as some individuals experience no improvement despite extensive use and research. Genetic factors can play a significant role, and standard treatments may not be effective for all.

A user has been using dutasteride and oral minoxidil for hair loss with no change and is considering a hair transplant at age 22. Replies suggest that a transplant is possible if DHT blockers like finasteride are continued, and another user shared a positive personal experience with a transplant at age 20.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

A user shared their 6-month progress after a hair transplant, continuing to use 0.5mg dutasteride and minoxidil daily, along with red light laser therapy. They recommend hair transplants for those who haven't had success with medical treatments.

The user experienced significant hair regrowth using KX-826 (pyrilutamide) 0.9% over one year, despite initial shedding phases. They reported no side effects and have stabilized hair loss with consistent use.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.

A user is using a Finoxidil topical spray and is curious if oral Finasteride would be more effective, considering they are already on a DHT blocker called Cyproterone. They are concerned about the potential impact of oral Finasteride on their transition.

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

After 10 months, the user's hairline and midscalp look thick following a 6100 graft FUE hair transplant in Turkey. They plan to address the crown in a few months.

A user shared a 10-month update on their hair transplant (HT), expressing significant confidence gain and recommending the procedure to others. They had the transplant in Turkey for $2300 and are very satisfied with the results.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

The user has been using minoxidil for hair loss and is considering trying a compounded topical treatment with 0.1% dutasteride, minoxidil, tretinoin, collagen, and silicon, as recommended by a trichologist. They learned that dutasteride might be more effective than finasteride and are seeking opinions on the use of topical dutasteride.

Hair cloning may become available in 1-2 years in Japan, but widespread availability and affordability could take 7-15 years. Current treatments like finasteride are effective but may lose effectiveness over time.

A 24-year-old shared their successful hair restoration journey, which included a hair transplant in Turkey, dutasteride, and topical minoxidil. They also started testosterone replacement therapy, which improved their quality of life and hair condition, and they now feel confident and satisfied with the results.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

A female user in her mid-20s with androgenetic alopecia and suspected telogene effluvium who has been taking Dutasteride, Spironolactone, Minoxidil, Dermarolling, Ketoconazol shampoo, and Yaz contraception for her hair loss for the past 6 months. She had a small shed during this time that she believes to be stress related.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

A 22-year-old with advanced diffuse thinning is considering oral dutasteride after stopping finasteride due to side effects like brain fog and testicular pain. They are also contemplating a hair transplant combined with oral dutasteride and topical finasteride, noting a thick donor area.

An 18-year-old male is experiencing hair loss and is using topical minoxidil and oral finasteride. He is concerned about continued shedding, mild sexual side effects, and whether to adjust his finasteride dosage.

A user has been using finasteride and minoxidil for hair loss without success and is considering switching to dutasteride. They are concerned about low DHT levels and are seeking advice on how to implement dutasteride effectively.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.